My career is the fruit of my creativity and dynamic way of working. Since my establishment as principal investigator, I have corresponded original works in Nature (2017), Nature Cell Biology (2016), Nature Communications (2016) and Cancer Research (2017, 2018). This trajectory as an independent researcher certifies my previous productivity as a PhD student (2002-2006) and a postdoctoral researcher (2007-2010) (Cancer Cell, Cancer Research, JCI, Nature Medicine). Importantly, I have influenced the field with relevant scientific reviews (Nature Reviews Cancer, Cell Metabolism, Cell, Trends in Endocrinology and Metabolism, Science Advances) and the organization of internationally recognised congresses in the field of cancer metabolism (EMBO 2014, EMBO 2016, EACR 2018, and the establishment of an agreement for the realization of congresses on tumour metabolism under the aegis of the EACR Conference Series in 2020). This in turn has granted me several awards recognizing my achievements in cancer research.
My career is based on answering and contributing to a fundamental question: what are the characteristics of the tumour cells that differentiate them from normal cells, and that can allow us to exploit this knowledge for the establishment of stratification strategies for patients and new therapies? My research group is aimed at deconstructing the essential requirements of cancer cells with special emphasis on the translation of the acquired knowledge from bench to bedside. In order to define the genuine features of cancer cells, we focus on the signalling and metabolic alterations in tumours. Through a multidisciplinary approach with increasing complexity, we work on ioinformatics, cell lines and primary cultures (using cell and molecular biology technologies), mouse models of prostate cancer that are faithful to the human disease and the analysis of human specimens through the development of prospective and retrospective studies. My work stems from the hypothesis that cancer is driven by signalling and metabolic alterations that, once identified, can be targeted for therapy. CIC bioGUNE and our collaborator institutions offer state-of-the-art technologies (from OMICS to in vivo imaging), which enables us to build and answer our hypotheses with high level of confidence.